Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Chemotherapy in Stage IV MSI-H/dMMR Colorectal Cancer
NCT05239741Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2022
- Primary completion
- Sep 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in colorectal cancer (CRC), sponsored by Merck & Co.. Started Apr 2022; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05239741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239741.